C. difficile Infection Reduction in Long-Term Care: Early Recognition and Implementation of Contact Precautions Bite-Sized Learning





Paula St. Hill, MPH, a-IPC


TECHNICAL ADVISOR, INFECTION PREVENTION

Paula is a doctoral student with a diverse background in public health, infection control, epidemiology and microbiology. She enjoys public health and identifying ways to improve health outcomes, specifically those related to healthcareassociated infections. She has 10 years of health care experience.

Paula enjoys spending time with her friends and family.

Contact: paula.sthill@allianthealth.org





Leighann.Sauls@AlliantHealth.org
Georgia, Kentucky, North Carolina and Tennessee

Program Directors



Early Recognition and Contact Precautions

After this session, the learner should be able to:

- Implement decision-making strategies for enhancing early recognition of patients with C. difficile infections.
- Understand what contact precautions are, when to initiate for patients with suspected or confirmed C. difficile infections and when to discontinue contact precautions.



Early Recognition: Sign and Symptoms


- Watery diarrhea as often as 10 to 15 times a day
- Abdominal cramping and pain, which may be severe
- Rapid heart rate
- Dehydration
- Fever
- Nausea
- Increased white blood cell count
- Kidney failure
- Loss of appetite
- Swollen abdomen
- Weight loss
- Blood or pus in the stool



Contact Precautions

- Contact Precautions require the use of a gown and gloves on every entry into a resident's room. The resident is given dedicated equipment (e.g., a stethoscope and blood pressure cuff) and is placed into a private room. Residents on Contact Precautions should be restricted to their rooms except for medically necessary care and restricted from participation in group activities.
- Contact Precautions are recommended if the resident has acute diarrhea, draining wounds or other sites of secretions or excretions that are unable to be covered or contained or for a limited time during a suspected or confirmed MDRO outbreak investigation.






Early Recognition and Testing Flow Chart



Discontinuing Contact Precautions

- Discontinue precautions when diarrhea has resolved (i.e., the resident has < 3 unformed stools in a 24-hour period)
- Some studies suggest continuing Contact Precautions for 48 hours after the resolution of diarrhea due to continued C. difficile shedding, environmental contamination, and resident skin colonization (McDonald et al., 2018)
- Some facilities continue Contact Precautions through the completion of CDI antibiotic therapy (McDonald et al., 2018)
- In facilities with high rates of CDI, consider continuing Contact Precautions until discharge
- Consider extending Contact Precautions for residents that are incontinent and require considerable assistance with activities of daily living





Contact Precautions Implementation and Discontinuation Flowchart



Thank you! Please contact any member of the Patient Safety Team for further questions!



Paula St. Hill, MPH, A-IPC
Technical Advisor, Infection Prevention
Paula.Sthill@AlliantHealth.org



Amy Ward, MS, BSN, RN, CIC, FAPIC
Patient Safety Manager
Amy.Ward@AlliantHealth.org



Donald Chitanda, MPH, CIC, LTC-CIP
Technical Advisor, Infection Prevention
Donald.Chitanda@AlliantHealth.org



Erica Umeakunne, MSN, MPH, APRN, CIC Infection Prevention Specialist Erica.Umeakunne@AlliantHealth.org





Making Health Care Better Together ALABAMA · FLORIDA · GEORGIA · KENTUCKY · LOUISIANA · NORTH CAROLINA · TENNESSE





Alliant Health Solutions





This material was prepared by Alliant Health Solutions, a Quality Innovation Network–Quality Improvement Organization (QIN – QIO) under contract with the Centers for Medicare & Medicaid Services (CMS), an agency of the U.S. Department of Health and Human Services (HHS). Views expressed in this material do not necessarily reflect the official views or policy of CMS or HHS, and any reference to a specific product or entity herein does not constitute endorsement of that product or entity by CMS or HHS. Publication No. 12SOW-AHS-QIN-QIO TO1-NH TO1-PCH-3685-05/02/23

